Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in clinical vertebral fractures compared with placebo (low certainty).
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes wrist fractures compared with placebo (very low certainty).
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes withdrawals due to adverse events compared with placebo (very low certainty).
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in non‐vertebral fractures compared with placebo (moderate certainty).
The review found no eligible studies for this question.
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
The review found no eligible studies for this question.
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in non‐vertebral fractures compared with placebo (low certainty).
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes hip fractures compared with placebo (very low certainty).
Antiviral prophylaxis leads to lower CMV disease: all symptomatic CMV disease compared with placebo or no treatment (high certainty).
Antiviral prophylaxis probably leads to lower death due to CMV disease compared with placebo or no treatment (moderate certainty).
Antiviral prophylaxis leads to lower all‐cause death compared with placebo or no treatment (high certainty).
Antiviral prophylaxis leads to lower CMV infection compared with placebo or no treatment (high certainty).
Antiviral prophylaxis showed no clear difference in graft loss compared with placebo or no treatment (moderate certainty).
Antiviral prophylaxis showed no clear difference in acute rejection compared with placebo or no treatment (high certainty).
Antiviral prophylaxis showed no clear difference in leucopenia compared with placebo or no treatment (moderate certainty).
Antiviral prophylaxis showed no clear difference in kidney dysfunction compared with placebo or no treatment (low certainty).